Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | BPTF | Q12830 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8133040 | 0.97 | — | — | |
| SCHEMBL4741470 | 0.92 | — | — | |
| SCHEMBL11559490 | 0.86 | ALDH1A1 (0.48) | ATMGAAL3MBTL1MEN1KMT2A | |
| SCHEMBL8285857 | 0.80 | ATM (0.62) | ATMGAAL3MBTL1MEN1KMT2A | |
| SCHEMBL14349488 | 0.78 | ATM (0.59) | ATMGAAL3MBTL1MEN1KMT2A | |
| SCHEMBL4602646 | 0.77 | ATM (0.65) | ATMGAAL3MBTL1MEN1KMT2A | |
| SCHEMBL18928680 | 0.77 | ATM (0.71) | ATMGAAL3MBTL1MEN1KMT2A | |
| SCHEMBL429744 | 0.76 | ATM (0.56) | ATMGAAL3MBTL1MEN1KMT2A | |
| SCHEMBL9040661 | 0.76 | ATM (0.56) | ATMGAAL3MBTL1MEN1KMT2A | |
| SCHEMBL429743 | 0.76 | ATM (0.56) | ATMGAAL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11229624-B2 | FABP4 as a therapeutic target in skin diseases | TICURE LTD. (IL) | 2022-01-25 | — | — | US | disclosed |
| US-20200138779-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | TICURE LTD. (IL) | 2020-05-07 | — | — | US | disclosed |
| US-20190144464-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2019-05-16 | — | — | US | disclosed |
| US-10221190-B2 | Biguanide compounds and use thereof | IMMUNOMET THERAPEUTICS INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-9549938-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| EP-2254880-B1 | Macrocyclic prodrug compounds useful as therapeutics | NEXGENIX PHARMACEUTICALS (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20150126518-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-05-07 | — | — | US | disclosed |
| WO-2009105755-A2 | MACROCYCLIC PRODRUG COMPOUNDS USEFUL AS THERAPEUTICS | NEXGENIX PHARMACEUTICALS (US) | 2009-08-27 | — | — | WO | disclosed |
| EP-1694748-B1 | METHOD OF MODIFYING A FLUOROPOLYMERIC SUBSTRATE AND COMPOSITE ARTICLES THEREBY | 3M INNOVATIVE PROPERTIES CO (US) | 2008-04-23 | — | — | EP | disclosed |
| US-20080090891-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090891-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-04-17 | — | — | US | disclosed |
| US-20070281937-A1 | Ion Channel Modulators | SCION PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-7273531-B2 | Method of modifying a fluoropolymeric substrate and composite articles thereby | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-09-25 | — | — | US | disclosed |
| EP-1694748-A1 | METHOD OF MODIFYING A FLUOROPOLYMERIC SUBSTRATE AND COMPOSITE ARTICLES THEREBY | 3M Innovative Properties Company (US) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005047373-A1 | METHOD OF MODIFYING A FLUOROPOLYMERIC SUBSTRATE AND COMPOSITE ARTICLES THEREBY | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050092429-A1 | Method of modifying a fluoropolymeric substrate and composite articles thereby | 3M INNOVATIVE PROPERTIES COMPANY | 2005-05-05 | — | — | US | disclosed |
| US-6153178-A | A KERATIN-REDUCING AGENT CONTAINING A MERCAPTO ACETAMIDE WITH CYCLIC AMINE GROUP FOR HAIR STYLING | WELLA AKTIENGESELLSCHAFT (DE) | 2000-11-28 | — | — | US | disclosed |
| US-3976769-A | INSECTICIDE | AIRWICK INDUSTRIES, INC. (US) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281937-A1 | Ion Channel Modulators | CACNA1B, CACNA1C, TRPV1 | ATM 4312/4885GAA 1560/4885L3MBTL1 3558/4885 |
| US-20190144464-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | GCKR, GCG, SLC5A2 | ATM 1178/4885GAA 95/4885L3MBTL1 3921/4885 |
| US-11229624-B2 | FABP4 as a therapeutic target in skin diseases | FABP4, FABP2, FABP1 | ATM 3596/4885GAA 1820/4885L3MBTL1 2540/4885 |
| US-20200138779-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | FABP4, FABP2, FABP1 | ATM 3596/4885GAA 1820/4885L3MBTL1 2540/4885 |
| US-20150126518-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | GCKR, GCG, SLC5A2 | ATM 1178/4885GAA 95/4885L3MBTL1 3921/4885 |
| US-10221190-B2 | Biguanide compounds and use thereof | GCKR, GCG, SLC5A2 | ATM 1178/4885GAA 95/4885L3MBTL1 3921/4885 |
| US-20080090891-A1 | ION CHANNEL MODULATORS | CACNA1B, CACNA1C, TRPV1 | ATM 4312/4885GAA 1560/4885L3MBTL1 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.